Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, ...

Viral hepatitis is a leading cause of liver disease, liver cancer and liver transplant in the United States and is a focus of an annual national awareness campaign that occurs ...

The first model is the redesigned Hesagraph Cannoli. The original version of this model was part of the brand’s first drop in ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. The three main types—Hepatitis A, B, ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of ...

The 37-year-old Stanford medical school graduate and author describes herself as a "former surgeon turned metabolic health ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...